MET and non-small cell lung carcinoma: TKI glesatinib (Figure 1A), a c-MET/SMO dual inhibitor (32, 33), is now under Phase II clinical trials in combination with Nivolumab in treatment of the non-small cell lung cancer (NSCLC).